Claret Bioscience LLC
Worcester, MA Part of Edenroc Sciences, LLC
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- Corporate family
-
-
Parent
Worcester, MA
GCJPLLTXJM53
-
- Scotts Valley, CA HLWAKMNJ1XC8
-
-
Parent
Worcester, MA
GCJPLLTXJM53
- SAM.gov registration date
- Physical address
- 100 Barber Ave, Worcester, MA 01606, USA
- Website
- claretbio.com
- Founded
- 2017
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $4,917 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| DNA extraction supplies for barcode of life | Smithsonian Institution | $4,917 |
Grant awards
Similar vendors
About the company
Claret Bioscience LLC is a for-profit limited liability company that specializes in developing innovative genomic and transcriptomic technologies for next-generation sequencing (NGS) applications. Registered to receive federal awards since June 2017, the company has secured both federal contracts and grants to support its research and development efforts. Claret Bioscience focuses on creating advanced molecular biology techniques that enhance the efficiency and sensitivity of DNA and RNA sequencing, particularly for challenging sample types such as cell-free nucleic acids and small RNA species.
In terms of federal contracts, Claret Bioscience has provided DNA extraction supplies for the Barcode of Life project. The company received a purchase order contract from the Smithsonian Institution, a civilian agency, in December 2022. This contract, valued at $4,917.00, was for the supply of specialized materials used in DNA extraction processes, which are crucial for genetic barcoding initiatives. The contract was not designated as a set-aside, indicating it was open to general competition. This award demonstrates Claret Bioscience's capability to provide high-quality reagents and supplies for genomic research applications to federal institutions.
Claret Bioscience has been particularly active in securing federal grants to support its research and development efforts in advanced sequencing technologies. The company has received multiple project grants from the National Institutes of Health, specifically from the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI). These grants have funded the development of novel NGS library preparation methods for various applications. A recent grant from NHGRI, awarded in February 2024, supports the development of a rapid miRNA profiling methodology called "miREALLY" for improved cancer diagnosis and monitoring. Another NHGRI grant from September 2021 funded the creation of a single-strand ligation approach for simultaneous DNA and RNA sequencing from low-abundance inputs, aimed at enhancing liquid biopsy-based diagnostics. Additionally, an earlier grant from the NCI in 2019 supported the development of a fast, scalable, and cost-effective single-stranded library protocol for cell-free DNA analysis. These grants highlight Claret Bioscience's focus on advancing NGS technologies for various biomedical applications, particularly in the areas of cancer research and precision medicine.
Quick answers
Is Claret Bioscience LLC registered in SAM.gov?
Yes. Claret Bioscience LLC's SAM.gov registration is active through August 13, 2027.
What is Claret Bioscience LLC's CAGE code?
Claret Bioscience LLC's CAGE code is 7XJ80, and its Unique Entity ID (UEI) is NBKDPRMF8Y27.
How much has Claret Bioscience LLC received in federal contracts?
Federal contracts obligated $4,917 to Claret Bioscience LLC in fiscal years 2023 through 2027.
What is Claret Bioscience LLC's most recent federal award?
Claret Bioscience LLC's most recent federal grant award is A rapid method for global and targeted mirna next generation sequencing (R43HG013444), from National Human Genome Research Institute (NIH), on February 15, 2024.
On GovTribe
See Claret Bioscience LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors